World's First Personalized Cancer Vaccine Dramatically Reduces Melanoma Recurrence Risk
A groundbreaking clinical trial led by an Australian scientist shows a new mRNA vaccine combined with immunotherapy significantly lowers the chances of melanoma returning or leading to death.
A Sydney-based scientist is at the forefront of a pioneering clinical trial for a personalized cancer vaccine that has demonstrated a remarkable ability to reduce the risk of melanoma recurrence and mortality. The study revealed that the vaccine, when used in conjunction with the immunotherapy drug pembrolizumab (Keytruda), cut the risk of cancer recurrence or death by 42% compared to using immunotherapy alone.
These findings hold significant promise for the future of cancer treatment, potentially paving the way for individualized cancer vaccines to improve survival rates not only for melanoma patients but possibly for those with other forms of cancer as well.
Professor Georgina Long, the principal investigator for the trial, also serves as the medical director of Melanoma Institute Australia and holds the chair of melanoma medical oncology and translational research at the University of Sydney. "These results show that patients with earlier-stage melanoma can be treated after surgery in a fundamentally new way," Professor Long stated. "These results are more than a landmark for melanoma. Just as email transformed how we communicate, individualised neoantigen therapy has the potential to transform how we treat cancer."
The investigational vaccine, known as intisomeran, is a collaborative development between pharmaceutical companies Moderna and MSD. It is an individualized messenger RNA (mRNA) vaccine designed to target the unique genetic characteristics of each patient's tumor.
The international clinical trial enrolled 1,137 participants across 157 sites. All participants had their melanoma surgically removed but were identified as being at high risk of the cancer returning. None had received prior drug treatment for their condition.
Australian sites involved in the trial included Melanoma Institute Australia, Westmead Hospital in New South Wales, Princess Alexandra Hospital in Queensland, and the Paula Fox Melanoma and Cancer Centre and Peter MacCallum Cancer Centre in Victoria.